Get the free Technical Report: Placebo-controlled double-blind study to determine the efficacy of...

This technical report presents findings from a clinical trial aimed at assessing the effectiveness of topical niclosamide lotion in preventing Schistosoma haematobium infections among Egyptian farmers.

How to fill out technical report placebo-controlled double-blind

How to fill out Technical Report: Placebo-controlled double-blind study to determine the efficacy of topical niclosamide 1% lotion in the prevention of naturally occurring Schistosoma haematobium infection in Egyptian farmers

1. Title: Clearly state the title of the study including the key components: placebo-controlled double-blind, topical niclosamide 1% lotion, and Schistosoma haematobium.
2. Abstract: Write a concise summary of the aims, methods, results, and conclusions of the study.
3. Introduction: Provide background information on Schistosoma haematobium infection, the rationale for using topical niclosamide, and the objectives of the study.
4. Methods: Detail the study design, including participant selection, randomization process, dosage of lotion, and method of blinding.
5. Results: Present the data collected during the study, using tables and figures where necessary to illustrate findings clearly.
6. Discussion: Analyze the results in context of existing literature, discuss the implications for Egyptian farmers, and suggest future research directions.
7. Conclusion: Summarize the main findings and their potential impact on public health and prevention strategies.
8. References: List all sources cited in the report according to the appropriate citation style.

Who needs Technical Report: Placebo-controlled double-blind study to determine the efficacy of topical niclosamide 1% lotion in the prevention of naturally occurring Schistosoma haematobium infection in Egyptian farmers?

1. Researchers and scientists studying Schistosoma infections and treatment options.
2. Public health officials and policymakers involved in disease prevention and control.
3. Medical professionals working in endemic areas where Schistosoma haematobium is prevalent.
4. Pharmaceutical companies considering the development of topical treatments for parasitic infections.
5. Agricultural health organizations focusing on the welfare of farmers at risk of parasitic infections.

People Also Ask about

How effective is praziquantel for humans?

Praziquantel is an isoquinoline compound that is used to treat human schistosomiasis on a large scale. It is a safe, nontoxic drug that is given orally in a single dose of 40 mg/kg of body weight and is highly effective against all human schistosomes, with cure rates of 80% to 90%.

What is the efficacy of the treatment of schistosomiasis?

Overall, therapeutic efficacy, measured as the reduction in arithmetic mean of schistosome egg counts following drug administration (egg reduction rate; ERR), was high for all three schistosome species (S. mansoni: 93.4% (95%CI: 88.8–96.8); S. haematobium: 97.7% (95%CI: 96.5–98.7) and S.

Why might praziquantel not work?

But praziquantel does have a number of limitations. First, it is only effective against adult parasites and a single treatment may not all worms, especially in individuals with high-intensity infections.

What is the efficacy of praziquantel treatment?

The pooled cure rate of praziquantel was the highest, 96.6% (95% CI: 88.5%–99.1%) among preschool children followed by 95.9% (95% CI: 86.3%–98.9%) among patients, 91.6% (95% CI: 89.8%–93.5%) in community based studies, and 87.8% (95% CI: 82.8%–92.8%) among schoolchildren (Figure 4).

What is the success rate of praziquantel?

The primary and secondary study outcomes were praziquantel efficacy (parasitological cure and egg reduction rates) and MDA-associated adverse events (AEs), respectively. Result: The overall cure rates at week-4 and week-8 were 89.1% (95%CI = 86.1–91.7) and 87.5% (95%CI = 83.6–90.8), respectively.

For pdfFiller’s FAQs

What is Technical Report: Placebo-controlled double-blind study to determine the efficacy of topical niclosamide 1% lotion in the prevention of naturally occurring Schistosoma haematobium infection in Egyptian farmers?

A Technical Report in this context is a comprehensive document that presents the methodology, findings, and implications of a clinical study testing the efficacy of a 1% topical niclosamide lotion in preventing Schistosoma haematobium infection among Egyptian farmers, which is a significant public health concern.

Who is required to file Technical Report: Placebo-controlled double-blind study to determine the efficacy of topical niclosamide 1% lotion in the prevention of naturally occurring Schistosoma haematobium infection in Egyptian farmers?

Researchers and clinical trial sponsors involved in conducting the study are required to file the Technical Report, ensuring that regulatory bodies and stakeholders are informed about the study's design, execution, and results.

How to fill out Technical Report: Placebo-controlled double-blind study to determine the efficacy of topical niclosamide 1% lotion in the prevention of naturally occurring Schistosoma haematobium infection in Egyptian farmers?

To fill out the Technical Report, researchers should include sections detailing the study objectives, methodology (including participant recruitment, randomization, and blinding), data collection and analysis methods, results, discussion of findings, conclusions, and any ethical considerations.

What is the purpose of Technical Report: Placebo-controlled double-blind study to determine the efficacy of topical niclosamide 1% lotion in the prevention of naturally occurring Schistosoma haematobium infection in Egyptian farmers?

The purpose of the Technical Report is to communicate the outcomes of the study to the scientific community and public health authorities, evaluate the effectiveness of the treatment, and contribute to the body of knowledge on controlling schistosomiasis in at-risk populations.

What information must be reported on Technical Report: Placebo-controlled double-blind study to determine the efficacy of topical niclosamide 1% lotion in the prevention of naturally occurring Schistosoma haematobium infection in Egyptian farmers?

The report must include a clear description of the study design, participant demographics, treatment protocols, outcomes measured, statistical analysis performed, results (including both primary and secondary outcomes), and conclusions drawn from the findings, along with any relevant references.